Results 151 to 160 of about 3,323,629 (269)
Prostate patient‐derived organoids (PDOs) were established from TURP and biopsy specimens with >90% success and retain key features of their tissues of origin, making them functional avatars for antisense oligonucleotide (ASO) therapy . Transfecting single cells outside the Matrigel matrix and then reconstituting organoids overcomes the 3D delivery ...
Thi Thom Tran +15 more
wiley +1 more source
The effects of exercise on treatment side effects for prostate cancer patients receiving androgen deprivation therapy: a systematic ...
Trish Livingston (13098306) +2 more
core
HOXC11 drives colorectal cancer progression by transcriptionally activating CAMK2A, which triggers NF‐κB–dependent CXCL5 upregulation. CXCL5–CXCR2 signaling further reinforces HOXC11 expression through the ERK1/2–SP1 axis, forming a prometastatic positive feedback loop that is effectively disrupted by combined CAMK2A and CXCR2 inhibition.
Qingyang Sun +12 more
wiley +1 more source
Reconsideration of progression to CRPC during androgen deprivation therapy [PDF]
Androgen blockade-naïve prostate cancer (PCa) develops into CRPC during androgen deprivation therapy (ADT) by various genetic actions. The androgen-AR signaling axis plays a key role in this development.
50248580 +5 more
core +1 more source
Androgen receptor (AR) drives copper accumulation in prostate cancer while inducing MTF1 to buffer copper toxicity. EP300‐mediated lactylation of MTF1 at K218 promotes its nuclear translocation and metallothionein expression, sequestering cytosolic copper and preventing mitochondrial cuproptosis.
Kai Li +21 more
wiley +1 more source
GSTM4 enhances the interaction between ACLY and the E3 ubiquitin ligase TRIM27, thereby increasing K48‐linked ubiquitination at the K554 site of ACLY and promoting its degradation. Consequently, GSTM4 regulates lipid synthesis, as well as the proliferation and metastasis of PCa cells, by modulating ACLY stability.
Kang‐Ping Xiong +11 more
wiley +1 more source
Salvage Androgen Deprivation Therapy Use After Definitive Radiotherapy With vs Without Androgen Deprivation Therapy in Prostate Cancer. [PDF]
Shen J +4 more
europepmc +1 more source
BJU International, Volume 138, Issue 6, Page 1007-1010, December 2026.
Arjun Nathan +13 more
wiley +1 more source
ABSTRACT Background Prophylactic pelvic nodal radiotherapy (PRT) aims to eradicate occult pelvic nodal disease in oligometastatic prostate cancer but increases lymphocyte exposure. Its early hematologic safety and lymphocyte recovery when added to radiotherapy to the prostate/prostate region and all imaging‐visible metastases remain uncertain.
Xin Qi +13 more
wiley +1 more source
Oxybutynin for hot flashes in men on androgen-deprivation therapy: interpreting the Alliance A222001 trial. [PDF]
Greenstein A +3 more
europepmc +1 more source

